CRM vs MRK: Which Is the Better Buy?
Side-by-side comparison of Salesforce, Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-08.
Salesforce, Inc. · Technology
$169.52
+45.0% upside to fair value
Grade A
High Quality
VS
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D
High Quality
QuantHub Verdict
CRM has more upside to fair value
(+45.0%).
CRM trades at a lower forward P/E
(19.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRM |
MRK |
| Current Price |
$169.52 |
$113.87 |
| Fair Value Estimate |
$245.80 |
$100.14 |
| Upside to Fair Value |
+45.0%
|
-12.1%
|
| Market Cap |
$138.8B |
$281.2B |
| Forward P/E |
19.6x
|
32.0x
|
| EV / EBITDA |
12.3x
|
17.3x
|
| Price / Sales |
3.2x
|
4.3x
|
| Price / FCF |
9.5x
|
19.9x
|
| Revenue Growth YoY |
+13.3%
|
+4.3%
|
| Gross Margin |
77.6%
|
75.9%
|
| Operating Margin |
21.9%
|
27.6%
|
| Return on Equity |
14.9%
|
17.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
10.56%
|
5.02%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Salesforce, Inc. is a leading provider of cloud-based software applications primarily focused on customer relationship management (CRM). The company exhibits high business quality with a durable competitive moat supported by strong gross margins of 77.6%, solid operating margin of 21.9%, and a robust return on equity of 14.9%. Recent quarterly revenue growth of 13.3% and earnings growth of 36.7% …
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
Accumulation Zones
| Metric |
CRM |
MRK |
| Zone Low |
$184.35 |
$75.11 |
| Zone High |
$208.93 |
$85.12 |
| In Buy Zone? |
Yes
|
No
|